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Abstract
Autism spectrum disorders (ASD) are classified as neurodevelopmental disorders characterised by diminished
social communication and interaction. Recently, evidence has accrued that a significant proportion of individuals with
autism have concomitant diseases such as mitochondrial disease and abnormalities of energy generation. This has
therefore led to the hypothesis that autism may be linked to mitochondrial dysfunction. We review such studies
reporting decreased activity of mitochondrial electron transport chain (ETC) complexes and reduced gene
expression of mitochondrial genes, in particular genes of respiratory chain complexes, in individuals with autism.
Overall, the findings support the hypothesis that there is an association of ASD with impaired mitochondrial function;
however, many of the studies have small sample sizes and there is variability in the techniques utilised. There is
therefore a vital need to utilise novel imaging techniques, such as near-infrared spectroscopy, that will allow non-
invasive measurement of metabolic markers for neuronal activity such as cytochrome c oxidase, in order to better
establish the link between autism and mitochondrial dysfunction.
Keywords: Autism; Mitochondrial dysfunction; Mitochondrial
health; Energy metabolism; Electron transport chain; Mitochondrial
deficiency
Introduction
Autism spectrum disorders (ASD) are classified as a group of
neurodevelopmental disorders which include autistic disorder,
Asperger’s syndrome, pervasive developmental disorder and childhood
disintegrative disorder. ASD is diagnosed on the basis of behavioural
observations such as impaired social interaction, diminished verbal
and non-verbal communication and repetitive behaviours [1]. ASD is
characterised through certain behavioural and cognitive features
which are primarily thought to be a result of atypical development of
the brain itself. Over recent years however, there is increasing evidence
indicating that a significant proportion of the ASD population have
implicating comorbidities such as mitochondrial dysfunction,
oxidative stress, gastrointestinal abnormalities and abnormalities in
regulation of the immune system [2]. In this context, autism may
involve, or be a result of, systemic physiological abnormalities rather
than entirely being a neurodevelopmental disorder.
The initial hypothesis associating ASD with an underlying
comorbidity such as mitochondrial dysfunction was made by Coleman
and Blass in 1985, who hypothesised that individuals with ASD can
have “abnormal carbohydrate metabolism” [3]. Later on, Lombard
made a similar proposition in 1998 [4] suggesting that “autism may be
a disorder of atypical mitochondrial function”. Since then, there have
been an increasing number of research and clinical studies involving
individuals with ASD and there is mounting evidence linking
mitochondrial dysfunction to ASD. We review the major findings from
studies that present evidence of mitochondrial dysfunction in ASD.
Prior to this, the reader is presented with a brief overview of the
mitochondria, mitochondrial genome, and the mitochondrial
mechanisms of energy generation, with particular reference to those
biochemical pathways discussed in the studies reviewed.
Mitochondrial Function
Mitochondria are cellular organelles that play a vital role in
ensuring the proper functioning of cells [5]. As the site of energy
generation, they are deemed the “powerhouse” of the cell and are
responsible for providing cells with energy to function. Mitochondria
are especially important in areas of high energy demand such as the
brain where neuronal cells utilise an estimated 4.7 billion ATP per
second [6]. ATP generation takes place through three major processes;
glycolysis which takes place in the cytosol, tricarboxylic acid (TCA)
cycle in the mitochondrial matrix and the electron transport chain
(ETC) in the inner mitochondrial membrane. In the first step of
glycolysis, glucose is broken down into pyruvate. Pyruvate then enters
the mitochondrial matrix where it is converted to the key intermediate
enzyme acetyl-CoA which is further used in the TCA cycle to reduce
electron carriers nicotinamide adenine dinucleotide (NAD) or NADH
in its reduced form and flavin adenine dinucleotide (FAD) or FADH2
in its reduced form. These high-energy electron carriers are then
transported to the inner mitochondrial membrane for the final stage
known as oxidative phosphorylation which takes place at the site of the
electron transport chain (ETC), in the inner mitochondrial membrane.
The respiratory chain comprises of different components, which
include five enzyme complexes I-V as well as two electron carriers;
ubiquinone and cytochrome c [2]. During this process, an initial
donation of electrons is made by the carriers NADH and FADH2 to
complexes I and II, respectively. These electrons are then passed down
through the remaining ETC complexes, down electrochemical gradient
to eventually produce ATP. Figure 1 shows the processes through
which ATP is generated in the mitochondria.
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Figure 1: Processes involved in energy generation and the mitochondrial respiratory chain. “Abbreviations: ADP, adenosine diphosphate; AKA,
α-Ketoglutarate; ATP, Adenosine Triphosphate; CoQ, Co-enzyme Q; Cyt C, Cytochrome C; e, electron; FAD, Flavin Adenine Dinucleotide;
FADH2, Reduced FAD; H, Hydrogen; LCFA, Long Chain Fatty Acid; MCFA, Medium Chain Fatty Acid; NAD, Nicotinamide Adenine
Dinucleotide; NADH, Reduced NAD; OXPHOS, Oxidative Phosphorylation; PDC, Pyruvate Dehydrogenase Complex; SCFA, Short Chain
Fatty Acid; TCA, Tricarboxylic Acid; I, complex I; II, complex II; III, complex III; IV, complex IV; V, complex V. The red arrows denote the flow
of electrons in the ETC” [2].
In addition to ATP synthesis, the mitochondria also play a number
of other important roles. These include calcium homeostasis through
regulation of Ca2+ signalling, regulation of apoptosis (cell death) and
production of reactive oxygen species (ROS) [7]. These diverse
mitochondrial functions coupled with the importance of the
mitochondria in the control of cellular energy demands imply that any
form of dysfunction could have serious consequences on the health of
an individual and may lead to disease. Mitochondrial disease has
already been linked to the pathogenesis of diseases such as and
Alzheimer’s [8].
Furthermore, mitochondria possess their own genome. Although
99% of mitochondrial proteins are coded for by nuclear DNA [9], the
ETC complexes contain subunits that are encoded both by
mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) [10]. The
mitochondrial genome has a total of 37 genes; 13 of which encode for
subunits of complexes I and III-V of the ETC and the rest-22 are
transfer RNAs (tRNAs) and 2 ribosomal RNAs (rRNAs) [11] the
machinery required for translation and transcription of the
mitochondrial genes into the ETC subunits. With both the nuclear and
mitochondrial genome regulating the gene expression of
mitochondrial proteins, mutations in either DNA could lead impaired
mitochondrial function as well as abnormalities in the ETC complexes.
Mitochondrial Dysfunction in ASD
Mitochondrial dysfunction can be classified into two types [12]; the
first type (“primary dysfunction”) refers to the dysfunction that occurs
as a result of a mutation in a gene that is directly involved in the ATP-
generating pathway. The second type (“secondary dysfunction”) refers
to the dysfunction occurring due to other genetic, biochemical or
metabolic abnormalities and deficiencies that may impair the
mitochondria’s ability to synthesise ATP. These biochemical markers of
mitochondrial dysfunction include “lactate, pyruvate, lactate-to-
pyruvate ratio, ubiquinone, alanine, alanine-to-lysine ratio and acyl-
carnitine”, all of which are produced at some stage of respiration [2].
We now review the major findings from studies that present
evidence of mitochondrial dysfunction in ASD. The findings from the
studies include a diverse range of results, some of which include
evidence of decreased activity of mitochondrial respiratory chain
complexes, evidence of the presence of biomarkers of oxidative stress
and mitochondrial dysfunction as well as indication of mtDNA
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mutations (deletions and replications). Table one summarises the
major findings from the studies discussed herein.
Evidence of Mitochondrial Dysfunction using Magnetic
Resonance Spectroscopy
Minshew et al. [13] conducted a study in 1993 using Phosphorus-31
magnetic resonance spectroscopy (31P MRS) and reported evidence of
mitochondrial energy metabolism abnormalities. The study
investigated brain energy and phospholipid metabolism in the dorsal
prefrontal cortex of autistic adolescents, by looking at
phosphocreatine, ADP, ATP, inorganic phosphate and
phosphomonoesters, phosphodiesters respectively. The study reported
abnormal metabolite levels for both brain energy and phospholipid
metabolism, in the group with ASD. Furthermore, these metabolite
levels were compared with scores from language and intelligence tests
within the same group. The study reported a positive correlation
between low intelligence and language scores and abnormal metabolite
levels in the autistic group, in comparison to controls.
Similar evidence has emerged for brain metabolic marker “N-acetyl-
aspartate” (NAA) using the same technique. NAA is an important
brain metabolite and a marker for mitochondrial dysfunction [14-16]
since it is synthesised solely by neuronal mitochondria and one of its
main functions includes contributing to the production of energy by
mitochondria. Reduced NAA concentrations were also reported in a
study conducted by Friedman et al. Friedman et al. in a group of 45
children with ASD, 13 typically developing (TD) controls and 15
children with development delay reported reduced in the ASD group
in comparison to the controls [17]. Furthermore, Ipser et al. [18]
conducted a study including autistic children and adults and found a
significantly lower levels of NAA in the white and grey matter of the
brains of the autistic children. Meanwhile across age, the study
reported significantly lower levels of NAA in the grey matter of the
cerebellum, the anterior cingulate cortex and parietal cortex.
Goldenthal et al. reported reduced NAA, phosphocreatine and
creatine levels in the left thalamus of children with autism [16].
Phosphocreatine and creatine provide information about cellular
energy metabolism that have a particularly important role in tissues
with high fluctuating energy demands. Furthermore, a more recent
study using proton spectroscopy conducted by the same group reports
decreased ratio of NAA to phosphocreatine (PCr) and creatine (Cr) in
the anterior white matter of children with autism [19].
Levels of Electron Transport Chain Complexes
As the ETC has a vital role in ATP production, many studies have
investigated the respiratory chain complexes for function, gene
expression levels and activity levels. A study conducted by Chauhan et
al. in 2011 examined a number of different areas of the post-mortem
brain tissue [20] (over a wide age range of individuals with ASD),
including the frontal, temporal, parietal and occipital cortices as well as
the cerebellum, to investigate the protein levels of the ETC complexes.
The results of this study demonstrated decreased levels of respiratory
chain complexes in the frontal and temporal cortex and the cerebellum
in the ASD group of children aged 4-10 years. Through further
investigation, the cerebellum was found to have decreased levels of
ETC complexes III and V, while the frontal cortex was reported to have
reduced levels of all respiratory chain complexes [20]. These results
were not found in the ASD group aged 14-39 years, therefore
suggesting brain region-specific developmental changes in the
respiratory chain complexes in ASD children. It could also suggest that
development of abnormalities in the respiratory chain could later on
lead to mitochondrial disease and potentially contribute to the onset of
autism symptoms. A similar study by Tang et al. [21] observed severe
ETC impairment with reduced levels of all ETC complexes (except
complex II) in children with ASD of age less than 10 years, in post-
mortem temporal lobe brain tissue. The study also found lower
complex I and IV enzyme activity.
Gu et al. in 2013 investigated the respiratory chain complexes as
well as pyruvate dehydrogenase activity in the post-mortem frontal
cortex tissue in 14 ASD individuals [22]. The study reported
significantly decreased pyruvate dehydrogenase activity (35%
reduction) along with reduced complex I and V activity, in the ASD
group. Pyruvate dehydrogenase is a key enzyme involved in conversion
of pyruvate to acetyl-CoA. Its reduced activity would result in
insufficient removal of pyruvate and lactate for the TCA cycle, causing
insufficient ATP generation. The results from this study support others
that have reported the association of mitochondrial dysfunction,
abnormal pyruvate and lactate levels [23,24], with autism by suggesting
that abnormal pyruvate dehydrogenase activity may play a role in high
levels of these metabolites in ASD.
A number of other studies investigated the activity of mitochondrial
ETC complexes in tissue other than brain. Giulivi et al. Investigated
mitochondrial dysfunction by studying lymphocytes in 10 children
with ASD and 10 controls [25]. Here too, the results demonstrated
impaired ETC complex I in the ASD group. They also reported on
pyruvate dehydrogenase activity which was found to be significantly
decreased (50%) in the ASD group. A more recent study conducted by
Goldenthal et al. investigated mitochondrial enzyme deficiencies in
buccal swabs of children with autism [15]. This study reports extensive
ETC abnormalities in 42% of the ASD group.
Although there are inconsistencies in the brain areas examined in
these studies, there is clear indication of the presence of abnormalities
in respiratory chain complexes in individuals with autism and these
may in fact play a role in the etiology of ASD. This can be explained by
the fact that the respiratory chain complexes are vital to energy
generation, particularly in an area of high energy demand such as the
brain. Their deficiency could lead to severe implications such as
insufficient energy metabolism and acceleration in production of free
radicals, resulting in oxidative stress.
Oxidative Stress
Reactive oxygen species (ROS) or free radicals are produced during
the metabolism of oxygen at the site of oxidative phosphorylation, the
electron transport chain. They are a molecular species that contain an
unpaired electron and are therefore highly reactive and unstable.
Although a regulated level of free radicals is required for key processes
such calcium homeostasis, they are capable of attacking important
macromolecules such as proteins and lipids, causing cell damage and
which can eventually lead to disease. Cell damage caused by ROS is
implicated in a number of diseases such as cancer [26,27] and
Alzheimer’s [8]. Several antioxidant defence mechanisms are employed
by the human body to maintain the level of free radicals and regulate
the damage they can cause. These defence mechanisms include the
production of antioxidant enzymes such as glutathione peroxidase and
superoxide dismutase (SOD) [5]. Mitochondrial dysfunction,
particularly deficiencies in the respiratory chain complexes, could lead
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to an elevated level of ROS thereby causing an imbalance of ROS
production/antioxidant defences, leading to oxidative stress.
Recent studies have demonstrated the co-occurrence of
mitochondrial abnormalities and oxidative stress in the post-mortem
brain tissue of children with ASD. As discussed earlier, the study by
Chauhan et al. [20] demonstrated brain region-specific deficiencies in
ETC complexes. This study additionally presented evidence of elevated
levels of ROS in the same brain regions where respiratory chain
complex deficiencies were observed. Similarly the study by Tang et al
[21] also discussed earlier reported elevated levels of biomarkers of
oxidative stress in the temporal cortex of the ASD group, the same
brain region where ETC complex deficiencies were observed.
Additionally, the same study reported significantly decreased activity
of antioxidant enzyme superoxide dismutase2, which plays an
important role in the defence mechanisms against ROS, in the group of
children with ASD. A different study by Giulivi et al. [25] reported
increased mitochondrial rate of production of antioxidant hydrogen
peroxide in the children with autism in comparison to controls.
An earlier study by Chauhan et al. investigated the presence of
markers of oxidative stress in brain tissue as well as in urine and blood
in a group of individuals with ASD [28]. The study revealed
significantly increased levels of these markers in the ASD group in
comparison to the controls, thereby strengthening the hypothesis that
oxidative stress may play a role in the etiology of autism [28].
Electron Transport Chain Gene Expression
Due to the recent implication of mitochondrial dysfunction in a
number of diseases such as Alzheimer’s [8,29] and cancer [27],
research groups have regained interest in field of mitochondrial
genetics and epigenetics. Many processes of mitochondrial gene
expression and regulation are, to date, not very well understood.
Various studies have set out to explore the variation of mitochondrial
gene expression in the respiratory chain enzymes, in individuals with
autism. In order to investigate this, one such study by Ginsberg et al.
used genome-wide genotyping and DNA methylation sequencing in
post-mortem brain tissue, namely cerebellar and occipital, from a
group 9 individuals with ASD and 9 controls [30]. The results of the
study presented evidence of down-regulation of the genes coding for
the ETC complexes I and III as well as ATP synthase.
Anitha et al. conducted a gene expression analysis study with
specific focus on the 84 genes encoding the mitochondrial respiratory
chain complexes [31]. The study examined three areas of post-mortem
brain tissue, namely the “anterior cingulate gyrus, motor cortex and
thalamus” areas in a group of 8 individuals with autism versus 10
controls. The results showed reduced gene expression in a number of
the genes coding for respiratory chain enzymes in the ASD group.
More specifically, in 11 genes coding for complex I, 5 of those coding
for complex III and IV and 7 coding for complex V [31].
Mitochondrial DNA Mutations
More recently, studies have utilised real-time polymerase chain
reaction (q-PCR) technique to look at mitochondrial DNA copy
number in individuals with ASD. DNA copy number variation is a
form of structural variations of DNA results in (ab)normal variation in
the number of copies of one or more sections of DNA. The study
conducted by Gu et al. [22], as discussed earlier, found deficient ETC
complexes and decreased pyruvate dehydrogenase activity. The group
additionally investigated copy number variations (CNVs) of
mitochondrial respiratory chain genes. “CNVs are the most common
types of structural variations in the human genome” [22]. The results
demonstrated increased CNVs in 3 respiratory chain genes encoding
for subunits of complex I and III a result that was also presented in the
study by Giulivi et al. in the lymphocytes of ASD individuals [25]. A
more recent study conducted by Chen et al. [32] shows results
consistent with the study conducted by Gu et al. The study reports
mtDNA copy number to be significantly elevated in in peripheral
blood cells in children with autism.
Conclusion
Autism is classified as a psychiatric disorder which is characterised
entirely by behaviours. Recent studies however, have presented
evidence for systemic physiological abnormalities in ASD. The studies
reviewed herein provide support to the idea of a link between
mitochondrial dysfunction and the behavioural phenotype of autism.
A number of different techniques have been employed to investigate a
range of potential aspects of this link and many have reported
decreased mitochondrial gene expression, decreased activity of
electron transport chain complexes and abnormal levels of peripheral
markers of mitochondrial function. However, due to the variation and
inconsistency in techniques used, there are limitations to the studies
reviewed here. These limitations make it difficult to determine whether
mitochondrial dysfunction is a feature of all individuals with ASD,
whether it is a cause or an effect of autism and whether such
dysfunctions are localised to specific regions of the brain. Even in light
of these however, there are consistent encouraging findings across the
different studies and methodologies, indicating that mitochondrial
disease may be commonly linked with autism and may be critical in
the causal pathway that determines atypicalities in brain function and
structure in autism. While further work is required, many studies have
reported a stronger association between mitochondrial abnormalities
and ASD in children, thereby providing indirect support for a causal
role.
Majority of the studies reviewed have examined the post-mortem
brain tissue of individuals with ASD. While this is an important step in
investigating a potential link between mitochondrial dysfunction and
autism, it does not provide the prospective insight that in vivo
investigation could deliver. Near-infrared spectroscopy (NIRS) is an
optical imaging technique that allows in vivo measurement of
chromophore concentration changes, which can be used to derive a
measure of cerebral oxygenation changes. With recent developments in
the NIRS imaging technique, novel NIRS systems allow investigation
of mitochondrial function in vivo by measuring optical changes in the
brain resulting from oxidative phosphorylation involving
mitochondrial electron transport chain enzyme cytochrome-c-oxidase
[33,34]. Studies in animals and humans have demonstrated that these
changes, measured following hypoxic ischemia, to be correlated with
31Phosphorus magnetic resonance spectroscopy (MRS) biomarkers of
cerebral energy failure. Thereby providing evidence for the potential of
measuring changes in mitochondrial function resulting from regional
changes in the brain induced by neural activity [35]. Adapting these
novel NIRS systems for use in children with ASD is an exciting step
which can provide useful insight into the role of mitochondrial
function in autism. Additionally, it could provide the opportunity to
explore whether mitochondrial dysfunction is a causal effect of autism
and how its development occurs in the ASD brain.
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Citation ASD Cases/Controls Methods Major findings
Minshew et al. [13] 11/11 Phosphorus-31 magneticresonance spectroscopy
Markers of mitochondrial function were abnormal in ASD brain and correlated with
ASD behaviours
Friedman et al. [17] 45/28 Echo planar spectroscopicimaging
“Reduced metabolite N-acetyl-aspartate1 (NAA) concentrations in the ASD group
compared to typically developing children”





“Higher ETC complex IV activity in ASD group”
“ASD group showed higher level of oxidative damage to mitochondrial proteins in
Brodmann Area (BA) BA41/422 or BA223”







“Mitochondrial dysfunction, mitochondrial DNA over replication and mitochondrial
DNA deletions were more likely in ASD group”
Chauhan et al. [20] 8/8 Western blotting “Decreased ETC complex activity in the frontal lobe, temporal lobe and cerebellumin ASD group”
Anitha et al. [31] 8/10 Quantification of geneexpression (q-PCR)
“Decreased expression of mitochondrial genes in anterior cingulate gyrus, motor
cortex and thalamus in ASD group”





“Decreased ETC complex gene expression in cerebellum and BA194 in ASD group
Rose et al. [37] 15/15




“Decreased aconitase5 activity in cerebellum and BA22 in ASD group”
Smith et al. [38] 69/89 Microarray analysis for copynumber variation
“Copy number variants (CNV) in autistic patients commonly encompass genes
important in mitochondrial function, ion transport and synaptic structure and
function”
Anitha et al. [31] 8/10 Quantification of geneexpression (q-PCR)
“Reduced expression of ETC genes (complexes I, III, IV and V) in the anterior
cingulate gyrus, thalamus, motor cortex in ASD group”




“Reduced ETC complex I and V activity in the frontal lobe in ASD group”
“Higher mitochondrial DNA copy number compared to nuclear DNA in 3 different
mitochondrial genes found in ASD group”
Tang et al. [21] 20/25
Western blotting
Quantification and
assessment of mtDNA (q-
PCR and long-range PCR)
Protein quantification
“Reduced ETC activity complexes I and IV in BA216 in ASD group”
“Higher levels of mitochondrial fission proteins and lower levels of mitochondrial
fusion proteins in BA21 of ASD group”
Chen et al. [32] 78/83 mtDNA copy numberanalysis (q-PCR) “Elevated mtDNA copy number in peripheral blood cells of children with autism”
Hardan et al. [19] 17/17 Proton magnetic resonancespectroscopy (1H MRS) Decreased ratio of NAA to phosphocreatine and creatine in children with ASD





Significant mitochondrial respiratory complex chain deficiencies in 42% of children
with ASD
Table 1: Summary of major findings from studies, including methods used. This table has been adapted from [5].
Notes
The definitions of the Brodmann areas defined below were taken
from [39].
1. “NAA is synthesized in the mitochondria of neurons. One of its
functions is to contribute to energy production from the amino acid
glutamate in neuronal mitochondria” [14].
2. “Brodmann area is a region of the cerebral cortex, in the human
or other primate brain, defined by its structure and organization of
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cells. BA41/42 is Brodmann areas 41 and 42 respectively that are
involved in auditory processing.”
3. “BA22 is the Brodmann area 22 region of the human brain. On
the left side of the brain this area helps with generation and
understanding of individual words. On the right side of the brain it
helps to discriminate pitch and sound intensity.”
4. “BA19 is the Brodmann area 19 region of the human brain. It is
part of the occipital lobe cortex and along with area 18; it comprises
the extrastriate (or peristriate) cortex. In humans with normal
sight, extrastriate cortex is a visual association area, with feature
extracting, shape recognition, and multimodal integrating functions.”
5. Aconitase is an enzyme primarily located in the mitochondria
involved in the TCA cycle.
6. “BA21 is Brodmann area 21 and it is part of
the temporal cortex in the human brain. The region encompasses most
of the lateral temporal cortex, a region believed to play a part in
auditory processing and language.”
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